Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 3/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27509393 | 0.99 | CTSS (0.51) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL28205495 | 0.87 | ATM (0.52) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL6345188 | 0.86 | CTSK (0.51) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL29077117 | 0.86 | ATM (0.51) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL30759366 | 0.84 | ITGA4 (0.51) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL487422 | 0.84 | ITGA4 (0.51) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL487423 | 0.84 | ITGA4 (0.51) | ATMKLK5CTSSCTSKCTSL | |
| SCHEMBL5994752 | 0.82 | SRR (0.47) | — | |
| SCHEMBL8583257 | 0.81 | ALPI (0.47) | — | |
| SCHEMBL28251018 | 0.81 | CTSK (0.52) | ATMCTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247582-A2 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME | Aventis Pharma S.A. (FR) | 2010-11-10 | — | — | EP | claimed |
| WO-2009115655-A2 | CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING SAME | AVENTIS PHARMA S.A. (FR) | 2009-09-24 | — | — | WO | claimed |
| EP-2791122-A1 | CRYSTALLINE FORM OF CABAZITAXEL AND PROCESS FOR PREPARING THE SAME | Aventis Pharma S.A. (FR) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088335-A1 | CRYSTALLINE FORM OF CABAZITAXEL AND PROCESS FOR PREPARING THE SAME | AVENTIS PHARMA S.A. (FR) | 2013-06-20 | — | — | WO | disclosed |
| WO-2010128258-A1 | ANTITUMOR COMBINATION INCLUDING CABAZITAXEL AND CAPECITABINE | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | WO | disclosed |
| EP-1694660-A1 | PROCESS FOR THE PREPARATION OF ANHYDROUS AND HYDRATED ACTIVE PHARMACEUTICAL INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SAID COMPOSITIONS | Quiral Quimica Do Brasil (BR) | 2006-08-30 | — | — | EP | disclosed |
| EP-1140064-B1 | ORAL ADMINISTRATION OF TAXOID DERIVATIVES | AVENTIS PHARMA SA (FR) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005061474-A1 | PROCESS FOR THE PREPARATION OF ANHYDROUS AND HYDRATED ACTIVE PHARMACEUTICAL INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PREPARED FROM THE SAME AND USES OF SAID COMPOSITIONS | QUIRAL QUÍMICA DO BRASIL (BR) | 2005-07-07 | — | — | WO | disclosed |
| US-6403634-B1 | FOR TREATING ABNORMAL CELL PROLIFERATION | AVENTIS PHARMA S.A. (FR) | 2002-06-11 | — | — | US | disclosed |
| US-6346543-B1 | ADMINISTERING BACCATIN DERIVATIVE AS ANTICARCINOGENIC AGENT | AVENTIS PHARMA S.A. (FR) | 2002-02-12 | — | — | US | disclosed |
| EP-1140064-A2 | ORAL ADMINISTRATION OF TAXOID DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-10-10 | — | — | EP | disclosed |
| EP-1109547-A1 | NEW USE OF TAXOID DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-06-27 | — | — | EP | disclosed |
| EP-1105119-A2 | NEW USE OF TAXOID DERIVATIVES | Aventis Pharma S.A. (FR) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000041482-A2 | ORAL ADMINISTRATION OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-07-20 | — | — | WO | disclosed |
| EP-1020188-A1 | New use of taxoid derivatives | Aventis Pharma S.A. (FR) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000010547-A2 | NEW USE OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-03-02 | — | — | WO | disclosed |
| EP-0982028-A1 | New use of taxoid derivatives | Aventis Pharma S.A. (FR) | 2000-03-01 | — | — | EP | disclosed |
| EP-0982027-A1 | Taxoid derivatives for treating abnormal cell proliferation of the brain | Aventis Pharma S.A. (FR) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000009120-A1 | NEW USE OF TAXOID DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2000-02-24 | — | — | WO | disclosed |